Sepsis Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Sepsis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sepsis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sepsis Market Forecast
https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Sepsis Market Report:
• The Sepsis market size was valued approximately USD 2,807 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2024, Soon after securing $57 million in funding, Inflammatix launched a clinical trial to assess its diagnostic technology for managing patients with suspected acute infections or sepsis. The TIMED trial (NCT06637904) will utilize the company's TriVerity test-a blood-based diagnostic that examines 29 messenger RNAs (mRNAs) to quickly evaluate the body's immune response to infection. When run on Inflammatix's benchtop, cartridge-based analyzer, Myrna, the test enables emergency department clinicians to identify the type of infection and determine if sepsis is likely to develop.
• In April 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focused on macrophage reprogramming immunotherapy, today reported positive indications of effect and safety results from its Phase II study of AllocetraTM in sepsis patients, with 120 patients enrolled.
• In April 2024, AdrenoMed announced that the US FDA has granted Fast Track designation to its lead product candidate, enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment of septic shock.
• In 2023, the United States represented the largest share of the sepsis population among the 7MM, exceeding 55%.
• DelveInsight reports that in 2023, approximately 57% of all sepsis cases in the United States were classified as sepsis without organ dysfunction, followed by septic shock (24%) and severe sepsis (18%). These numbers are expected to rise during the forecast period from 2024 to 2034.
• According to the analysis, the four primary infection sites in sepsis patients are lung infections, urinary tract infections (UTIs), gut infections, and skin infections, representing approximately 43%, 30%, 13%, and 13% of all infection sites, respectively.
• The introduction of emerging sepsis therapies, including Allocetra by Enlivex Therapeutics and enibarcimab by Adrenomed, among others, is expected to have a significant impact on the sepsis diagnostic market during the forecast period from 2023 to 2034.
• Key Sepsis Companies: La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics, Ono Pharmaceuticals, Vivacelle Bio, Inotrem SA, Enlivex Therapeutics, and others
• Key Sepsis Therapies: GIAPREZA (angiotensin II), Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, and others
• The Sepsis epidemiology based on gender analyzed that in the 7MM, the majority of patient pool were males as compared to females whereas in the US female population dominated the Sepsis incident pool
• The Sepsis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sepsis pipeline products will significantly revolutionize the Sepsis market dynamics.

Sepsis Overview
Sepsis is a severe and potentially life-threatening condition that occurs when the body's response to an infection leads to systemic inflammation. The immune system's response to infection can sometimes become overactive, triggering widespread inflammation that can result in organ dysfunction or failure.

Get a Free sample for the Sepsis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sepsis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sepsis Epidemiology Segmentation:
The Sepsis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Sepsis
• Prevalent Cases of Sepsis by severity
• Gender-specific Prevalence of Sepsis
• Diagnosed Cases of Episodic and Chronic Sepsis

Download the report to understand which factors are driving Sepsis epidemiology trends @ Sepsis Epidemiology Forecast
https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sepsis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sepsis market or expected to get launched during the study period. The analysis covers Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sepsis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sepsis Therapies and Key Companies
• GIAPREZA (angiotensin II): La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics
• Onoact Injection (Landiolol hydrochloride): Ono Pharmaceuticals
• VBI-S: Vivacelle Bio
• Nangibotide: Inotrem SA
• Allocetra: Enlivex Therapeutics

Discover more about therapies set to grab major Sepsis market share @ Sepsis Treatment Landscape
https://www.delveinsight.com/sample-request/sepsis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Sepsis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Sepsis Companies: La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics, Ono Pharmaceuticals, Vivacelle Bio, Inotrem SA, Enlivex Therapeutics, and others
• Key Sepsis Therapies: GIAPREZA (angiotensin II), Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, and others
• Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
• Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Sepsis Unmet Needs, KOL's views, Analyst's views, Sepsis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.